Oncolytics Biotech Inc. Announces Issuance of 8th Canadian Patent
Oncolytics Biotech Inc. has been granted Canadian Patent 2,408,251 entitled "Clearance of Neoplastic Cells from Mixed Cellular Compositions using viruses." The claims describe methods of selectively removing cancer cells ex vivo from blood stem cells and other organs using various viruses including modified vaccinia viruses, herpes simplex viruses, parapoxviruses and adenoviruses.
"This patent broadens coverage in the area of using other modified oncolytic viruses to purge contaminating cancer cells from stem cell preparations used for transplants," said Dr. Matt Coffey, Chief Scientific Officer of Oncolytics.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Innovative microscopy technique reveals secrets of lipid synthesis inside cells - Two-color infrared photothermal microscopy (2C-IPM) opens new avenues for long-term study of lipid metabolism in living cells
Founder and CEO of German BRAIN AG, Dr. Holger Zinke, is awarded with the ”Deutschen Umweltpreis 2008“ - German biotech company pacemaker for sustainability
A ranking of environmental chemicals
